Aspirin does not reduce the clinical benefits of the mineralocorticoid receptor antagonist eplerenone in patients with systolic heart failure and mild symptoms: An analysis of the EMPHASIS-HF study

MLA

Chin, Ken Lee, et al. Aspirin Does Not Reduce the Clinical Benefits of the Mineralocorticoid Receptor Antagonist Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms: An Analysis of the EMPHASIS-HF Study. Jan. 2016. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.dedup.wf.001..4e2a0802c816f5a9a4a042793f475a7c&authtype=sso&custid=ns315887.

APA

Chin, K. L., Collier, T. J., Pitt, B., McMurray, J. J. V., Swedberg, K., van Veldhuisen, D. J., Pocock, S. J., Vincent, J., Turgonyi, E., Zannad, F., & Krum, H. (2016). Aspirin does not reduce the clinical benefits of the mineralocorticoid receptor antagonist eplerenone in patients with systolic heart failure and mild symptoms: An analysis of the EMPHASIS-HF study.

Chicago

Chin, Ken Lee, Timothy J. Collier, Bertram Pitt, John J. V. McMurray, Karl Swedberg, Dirk J. van Veldhuisen, Stuart J. Pocock, et al. 2016. “Aspirin Does Not Reduce the Clinical Benefits of the Mineralocorticoid Receptor Antagonist Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms: An Analysis of the EMPHASIS-HF Study,” January. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.dedup.wf.001..4e2a0802c816f5a9a4a042793f475a7c&authtype=sso&custid=ns315887.